SAB Historical Balance Sheet

SABSW Stock

USD 0.07 0 5.75%

Trend analysis of SAB Biotherapeutics balance sheet accounts such as Total Stockholder Equity of 36 M, Property Plant And Equipment Net of 25.2 M, Accounts Payable of 898.6 K or Cash of 59.4 M provides information on SAB Biotherapeutics' total assets, liabilities, and equity, which is the actual value of SAB Biotherapeutics to its prevalent stockholders. By breaking down trends over time using SAB Biotherapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining SAB Biotherapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether SAB Biotherapeutics is a good buy for the upcoming year.

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in SAB Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more information on how to buy SAB Stock please use our How to Invest in SAB Biotherapeutics guide.

About SAB Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of SAB Biotherapeutics at a specified time, usually calculated after every quarter, six months, or one year. SAB Biotherapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of SAB Biotherapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which SAB currently owns. An asset can also be divided into two categories, current and non-current.

SAB Biotherapeutics Balance Sheet Chart

At this time, SAB Biotherapeutics' Total Liabilities is fairly stable compared to the past year. Net Working Capital is likely to climb to about 50.5 M in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 5.5 M in 2024.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities Current Deferred Revenue

Total Assets

Total assets refers to the total amount of SAB Biotherapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in SAB Biotherapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on SAB Biotherapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of SAB Biotherapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most accounts from SAB Biotherapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into SAB Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in SAB Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more information on how to buy SAB Stock please use our How to Invest in SAB Biotherapeutics guide.At this time, SAB Biotherapeutics' Total Liabilities is fairly stable compared to the past year. Net Working Capital is likely to climb to about 50.5 M in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 5.5 M in 2024.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	6.7M	5.9M	5.9M	5.5M
Total Assets	79.4M	50.9M	83.9M	63.5M

Short Long Term Debt Total Total Assets

SAB Biotherapeutics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital
Total Assets		-0.73	0.81	0.87	0.98	0.95	-0.87	-0.56	0.26	0.86	0.94	0.92	0.86	0.26	-0.95	-0.41	-0.32	0.83	0.88	0.69	0.98	0.96	-0.86	0.99	-0.65	0.86
Short Long Term Debt Total	-0.73		-0.66	-0.64	-0.71	-0.76	0.86	0.87	0.3	-0.85	-0.76	-0.93	-0.85	0.33	0.68	0.39	0.86	-0.54	-0.82	-0.51	-0.72	-0.82	0.52	-0.68	0.8	-0.74
Other Current Liab	0.81	-0.66		0.98	0.71	0.88	-0.64	-0.31	0.25	0.62	0.88	0.82	0.62	0.15	-0.78	-0.27	-0.24	0.96	0.57	0.88	0.7	0.84	-0.89	0.74	-0.37	0.52
Total Current Liabilities	0.87	-0.64	0.98		0.79	0.94	-0.66	-0.28	0.39	0.64	0.94	0.84	0.64	0.32	-0.87	-0.42	-0.18	0.95	0.6	0.82	0.79	0.89	-0.96	0.79	-0.37	0.59
Total Stockholder Equity	0.98	-0.71	0.71	0.79		0.93	-0.85	-0.57	0.3	0.83	0.93	0.9	0.83	0.32	-0.97	-0.52	-0.35	0.71	0.9	0.54	1.0	0.95	-0.81	0.96	-0.64	0.86
Property Plant And Equipment Net	0.95	-0.76	0.88	0.94	0.93		-0.76	-0.46	0.37	0.74	1.0	0.93	0.74	0.33	-0.98	-0.6	-0.36	0.83	0.78	0.64	0.93	0.99	-0.92	0.88	-0.5	0.72
Net Debt	-0.87	0.86	-0.64	-0.66	-0.85	-0.76		0.86	0.2	-1.0	-0.76	-0.91	-1.0	0.16	0.74	0.22	0.58	-0.66	-0.9	-0.64	-0.85	-0.82	0.61	-0.89	0.94	-0.96
Retained Earnings	-0.56	0.87	-0.31	-0.28	-0.57	-0.46	0.86		0.59	-0.86	-0.46	-0.74	-0.86	0.54	0.43	0.12	0.86	-0.26	-0.81	-0.31	-0.58	-0.57	0.18	-0.59	0.95	-0.78
Accounts Payable	0.26	0.3	0.25	0.39	0.3	0.37	0.2	0.59		-0.21	0.36	0.0	-0.21	0.98	-0.46	-0.53	0.6	0.28	-0.08	0.01	0.3	0.26	-0.56	0.2	0.49	-0.06
Cash	0.86	-0.85	0.62	0.64	0.83	0.74	-1.0	-0.86	-0.21		0.74	0.9	1.0	-0.17	-0.73	-0.22	-0.57	0.65	0.88	0.63	0.83	0.8	-0.6	0.88	-0.94	0.97
Non Current Assets Total	0.94	-0.76	0.88	0.94	0.93	1.0	-0.76	-0.46	0.36	0.74		0.93	0.74	0.32	-0.98	-0.6	-0.37	0.82	0.79	0.64	0.93	0.99	-0.92	0.87	-0.5	0.72
Long Term Debt	0.92	-0.93	0.82	0.84	0.9	0.93	-0.91	-0.74	0.0	0.9	0.93		0.9	-0.02	-0.88	-0.46	-0.63	0.75	0.89	0.65	0.9	0.96	-0.76	0.87	-0.75	0.83
Cash And Short Term Investments	0.86	-0.85	0.62	0.64	0.83	0.74	-1.0	-0.86	-0.21	1.0	0.74	0.9		-0.17	-0.73	-0.22	-0.57	0.65	0.88	0.63	0.83	0.8	-0.6	0.88	-0.94	0.97
Net Receivables	0.26	0.33	0.15	0.32	0.32	0.33	0.16	0.54	0.98	-0.17	0.32	-0.02	-0.17		-0.45	-0.54	0.62	0.21	-0.06	-0.06	0.32	0.23	-0.51	0.22	0.42	0.01
Common Stock Shares Outstanding	-0.95	0.68	-0.78	-0.87	-0.97	-0.98	0.74	0.43	-0.46	-0.73	-0.98	-0.88	-0.73	-0.45		0.66	0.29	-0.75	-0.79	-0.53	-0.96	-0.97	0.9	-0.89	0.48	-0.75
Non Current Liabilities Total	-0.41	0.39	-0.27	-0.42	-0.52	-0.6	0.22	0.12	-0.53	-0.22	-0.6	-0.46	-0.22	-0.54	0.66		0.27	-0.14	-0.31	0.16	-0.52	-0.57	0.52	-0.29	0.05	-0.3
Capital Lease Obligations	-0.32	0.86	-0.24	-0.18	-0.35	-0.36	0.58	0.86	0.6	-0.57	-0.37	-0.63	-0.57	0.62	0.29	0.27		-0.06	-0.62	-0.09	-0.36	-0.47	0.02	-0.28	0.67	-0.43
Other Current Assets	0.83	-0.54	0.96	0.95	0.71	0.83	-0.66	-0.26	0.28	0.65	0.82	0.75	0.65	0.21	-0.75	-0.14	-0.06		0.55	0.95	0.7	0.78	-0.9	0.79	-0.4	0.59
Other Stockholder Equity	0.88	-0.82	0.57	0.6	0.9	0.78	-0.9	-0.81	-0.08	0.88	0.79	0.89	0.88	-0.06	-0.79	-0.31	-0.62	0.55		0.47	0.91	0.87	-0.53	0.9	-0.8	0.85
Total Liab	0.69	-0.51	0.88	0.82	0.54	0.64	-0.64	-0.31	0.01	0.63	0.64	0.65	0.63	-0.06	-0.53	0.16	-0.09	0.95	0.47		0.53	0.61	-0.72	0.69	-0.46	0.53
Net Invested Capital	0.98	-0.72	0.7	0.79	1.0	0.93	-0.85	-0.58	0.3	0.83	0.93	0.9	0.83	0.32	-0.96	-0.52	-0.36	0.7	0.91	0.53		0.95	-0.8	0.96	-0.64	0.86
Property Plant And Equipment Gross	0.96	-0.82	0.84	0.89	0.95	0.99	-0.82	-0.57	0.26	0.8	0.99	0.96	0.8	0.23	-0.97	-0.57	-0.47	0.78	0.87	0.61	0.95		-0.85	0.9	-0.58	0.76
Short Long Term Debt	-0.86	0.52	-0.89	-0.96	-0.81	-0.92	0.61	0.18	-0.56	-0.6	-0.92	-0.76	-0.6	-0.51	0.9	0.52	0.02	-0.9	-0.53	-0.72	-0.8	-0.85		-0.79	0.31	-0.62
Total Current Assets	0.99	-0.68	0.74	0.79	0.96	0.88	-0.89	-0.59	0.2	0.88	0.87	0.87	0.88	0.22	-0.89	-0.29	-0.28	0.79	0.9	0.69	0.96	0.9	-0.79		-0.7	0.89
Capital Stock	-0.65	0.8	-0.37	-0.37	-0.64	-0.5	0.94	0.95	0.49	-0.94	-0.5	-0.75	-0.94	0.42	0.48	0.05	0.67	-0.4	-0.8	-0.46	-0.64	-0.58	0.31	-0.7		-0.9
Net Working Capital	0.86	-0.74	0.52	0.59	0.86	0.72	-0.96	-0.78	-0.06	0.97	0.72	0.83	0.97	0.01	-0.75	-0.3	-0.43	0.59	0.85	0.53	0.86	0.76	-0.62	0.89	-0.9

Click cells to compare fundamentals

SAB Biotherapeutics Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for SAB Stock Analysis

When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

SAB Historical Balance Sheet

About SAB Balance Sheet Analysis

SAB Biotherapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Current Deferred Revenue

SAB Biotherapeutics balance sheet Correlations

SAB Biotherapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for SAB Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Invested Capital	+ 1.0	Total Stockholder Equity
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 0.99	Total Assets
Property Plant And Equipment Gross	+ 0.99	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 0.99	Non Current Assets Total

Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Common Stock Shares Outstanding	- 0.98	Non Current Assets Total
Common Stock Shares Outstanding	- 0.98	Property Plant And Equipment Net
Property Plant And Equipment Gross	- 0.97	Common Stock Shares Outstanding
Common Stock Shares Outstanding	- 0.97	Total Stockholder Equity